Anagrelide(BL416201), an imidazoquinazoline derivative, is an inhibitor of phosphodiesterase type III (PDEIII) with IC50 of 36 nM, which acts as an antithrombotic and platelet-reducing agent.

Amsacrine(m-AMSA; acridinyl anisidide) is an inhibitor of topoisomerase II. Amsacrine acts as an antineoplastic agent which intercalates into the DNA of tumor cells, it is also used in the treatment of acute myelogenous leukemia.

Anagrelide(BL416201), an imidazoquinazoline derivative, is an inhibitor of phosphodiesterase type III (PDEIII) with IC50 of 36 nM, which acts as an antithrombotic and platelet-reducing agent.

Anagrelide(BL416201), an imidazoquinazoline derivative, is an inhibitor of phosphodiesterase type III (PDEIII) with IC50 of 36 nM, which acts as an antithrombotic and platelet-reducing agent.

Anagrelide(BL416201), an imidazoquinazoline derivative, is an inhibitor of phosphodiesterase type III (PDEIII) with IC50 of 36 nM, which acts as an antithrombotic and platelet-reducing agent.

Anamorelin hydrochloride(RC-1291 HCL, ONO-7643) is a potent and selective agonist of ghrelin receptor with EC50 of 0.74 nM FLIPR assay. It has a significant appetite-enhancing activity and has the potential to treat cancer anorexia-cachexia syndrome.

Anamorelin hydrochloride(RC-1291 HCL, ONO-7643) is a potent and selective agonist of ghrelin receptor with EC50 of 0.74 nM FLIPR assay. It has a significant appetite-enhancing activity and has the potential to treat cancer anorexia-cachexia syndrome.

Anamorelin hydrochloride(RC-1291 HCL, ONO-7643) is a potent and selective agonist of ghrelin receptor with EC50 of 0.74 nM FLIPR assay. It has a significant appetite-enhancing activity and has the potential to treat cancer anorexia-cachexia syndrome.

Anamorelin hydrochloride(RC-1291 HCL, ONO-7643) is a potent and selective agonist of ghrelin receptor with EC50 of 0.74 nM FLIPR assay. It has a significant appetite-enhancing activity and has the potential to treat cancer anorexia-cachexia syndrome.

Allopurinol riboside, a metabolite of allopurinol, competitively inhibits the action of purine nucleoside phosphorylase on inosine in vitro with a Ki value of 277 μM. It displays potent activities against parasites.